Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

Company Pauses OV101 Program Based On NEPTUNE Results

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

nerve cells, concept for neurodegenerative and neurological disease
Ovid shifts focus after Phase III Angelman syndrome study disappoints. • Source: Shutterstock

Ovid Therapeutics, Inc. is hitting the pause button on its program to develop OV101 (gaboxadol) for Angelman syndrome following the failure of the Phase III NEPTUNE trial. The company plans a full analysis of trial data and further discussions with the US Food and Drug Administration.

OV101 was Ovid's lead asset, but now the company will turn its attention to OV935 (soticlestat) in Dravet syndrome and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category